Early antiretroviral therapy and mortality among HIV-infected infants
dc.contributor.author | Violari A. | |
dc.contributor.author | Cotton M.F. | |
dc.contributor.author | Gibb D.M. | |
dc.contributor.author | Babiker A.G. | |
dc.contributor.author | Steyn J. | |
dc.contributor.author | Madhi S.A. | |
dc.contributor.author | Jean-Philippe P. | |
dc.contributor.author | McIntyre J.A. | |
dc.date.accessioned | 2012-01-18T08:06:22Z | |
dc.date.available | 2012-01-18T08:06:22Z | |
dc.date.issued | 2008 | |
dc.description | Please help us populate SUNScholar with the post print version of this article. It can be e-mailed to: scholar@sun.ac.za | |
dc.identifier.citation | New England Journal of Medicine | |
dc.identifier.citation | 359 | |
dc.identifier.citation | 21 | |
dc.identifier.citation | http://www.scopus.com/inward/record.url?eid=2-s2.0-56749097184&partnerID=40&md5=771f5001a2360d51069d3b21f73e12e4 | |
dc.identifier.issn | 284793 | |
dc.identifier.other | 10.1056/NEJMoa0800971 | |
dc.identifier.uri | http://hdl.handle.net/10019.1/18879 | |
dc.subject | abacavir | |
dc.subject | didanosine | |
dc.subject | efavirenz | |
dc.subject | lamivudine | |
dc.subject | lopinavir plus ritonavir | |
dc.subject | nevirapine | |
dc.subject | stavudine | |
dc.subject | zidovudine | |
dc.subject | anemia | |
dc.subject | article | |
dc.subject | bacterial infection | |
dc.subject | CD4+ T lymphocyte | |
dc.subject | chronic lung disease | |
dc.subject | clinical trial | |
dc.subject | controlled clinical trial | |
dc.subject | controlled study | |
dc.subject | cytomegalovirus infection | |
dc.subject | disease course | |
dc.subject | drug dose regimen | |
dc.subject | drug safety | |
dc.subject | drug substitution | |
dc.subject | drug treatment failure | |
dc.subject | drug withdrawal | |
dc.subject | esophagus candidiasis | |
dc.subject | extrapulmonary tuberculosis | |
dc.subject | female | |
dc.subject | gastroenteritis | |
dc.subject | highly active antiretroviral therapy | |
dc.subject | human | |
dc.subject | Human immunodeficiency virus infection | |
dc.subject | hyperkalemia | |
dc.subject | hypernatremia | |
dc.subject | hypokalemia | |
dc.subject | hyponatremia | |
dc.subject | infant | |
dc.subject | interstitial pneumonia | |
dc.subject | major clinical study | |
dc.subject | male | |
dc.subject | meningitis | |
dc.subject | mortality | |
dc.subject | neutropenia | |
dc.subject | phase 3 clinical trial | |
dc.subject | Pneumocystis pneumonia | |
dc.subject | pneumonia | |
dc.subject | priority journal | |
dc.subject | randomized controlled trial | |
dc.subject | side effect | |
dc.subject | thrombocytopenia | |
dc.subject | treatment duration | |
dc.subject | treatment outcome | |
dc.subject | tuberculosis | |
dc.subject | virus transmission | |
dc.subject | wasting syndrome | |
dc.subject | Anti-HIV Agents | |
dc.subject | CD4 Lymphocyte Count | |
dc.subject | Disease Progression | |
dc.subject | Drug Administration Schedule | |
dc.subject | Drug Therapy, Combination | |
dc.subject | Female | |
dc.subject | Follow-Up Studies | |
dc.subject | HIV Infections | |
dc.subject | HIV-1 | |
dc.subject | Humans | |
dc.subject | Infant | |
dc.subject | Infectious Disease Transmission, Vertical | |
dc.subject | Lamivudine | |
dc.subject | Male | |
dc.subject | Pyrimidinones | |
dc.subject | Ritonavir | |
dc.subject | Treatment Failure | |
dc.subject | Zidovudine | |
dc.title | Early antiretroviral therapy and mortality among HIV-infected infants | |
dc.type | Article |